The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration
Abstract
Objective: The aim of the study was to assess the risk of venous thromboembolism (VTE) associated with systemic hormone therapy according to type and to route of administration and the risk of VTE associated with locally administered estrogen. Methods: In this case-control study, conducted in Sweden between 2003 and 2009, we included 838 cases of VTE and 891 controls with a mean age of 55 years. Controls were matched by age to the cases and randomly selected from the population. We used logistic regression to calculate odds ratios (ORs) with 95% CIs and adjusted for smoking, body mass index, and immobilization. Results: Current use of any hormone therapy was associated with an increased risk of VTE (OR 1.72, 95% CI 1.34-2.20). For estrogen in combination with progestogen the OR was 2.85 (95% CI 2.08-3.90), and for estrogen only the OR was 1.31 (95% CI 0.78-2.21). In orally administered estrogen combined with progestogen, the OR was slightly, but not significantly, higher among users of medroxyprogesterone acetate (OR 2.94, 95% CI 1.67-5.36) than among norethisterone acetate users (OR 2.55, 95% CI 1.50-3.40). Transdermal estrogen combined with progestogen was not associated with VTE risk (crude and imprecise ORs ranging from 0.87 to 1.16). For local effect of estrogen, there was no association with VTE risk (OR 0.69, 95% CI 0.43-1.10). Conclusions: The risk of VTE risk is higher in users of systemic combined estrogen–progestogen treatment than in users of estrogen only. Furthermore, the risk of VTE was lower for women who used local estrogen than among those using oral estrogen only. Transdermal estrogen only treatment and estrogen for local effect seem not to be related to an increased risk of VTE.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“observational studies reveal the potential for reduced risk for thromboembolism and dyslipidemia with transdermal delivery when compared to oral (209, 210).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [209]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Silverstein, M. D., Heit, J. A., Mohr, D. N., Petterson, T. M., O'Fallon, W. M., & Melton, L. J. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.6.585 · Cited by 2,660
Anderson, F. A. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400050081016 · Cited by 1,669
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 864
Grady, D., Wenger, N. K., Herrington, D., Khan, S., Furberg, C., Hunninghake, D., Vittinghoff, E., Hulley, S., & for the Heart and Estrogen/progestin Replacement Study Research Group (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-9-200005020-00002 · Cited by 715
Estrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569 · cited 2×
“Previous observational and randomized clinical trials (RCTs) reported increased risks of VTE among postmenopausal women using any HT comparing with nonusers.(7-12)”
BackgroundResultStanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Scarabin, P.-Y., Alhenc-Gelas, M., Plu-Bureau, G., Taisne, P., Agher, R., & Aiach, M. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.11.3071 · Cited by 348
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
The 2017 hormone therapy position statement of The North American Menopause Society
(2017) · Menopause · doi:10.1097/gme.0000000000000921 · Cited by 1,001
Hormone-replacement therapy: current thinking
Lobo, R. A. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.164 · Cited by 484
Crandall, C. J., Hovey, K. M., Andrews, C. A., Chlebowski, R. T., Stefanick, M. L., Lane, D. S., Shifren, J., Chen, C., Kaunitz, A. M., Cauley, J. A., et al. (2018) · Menopause · doi:10.1097/gme.0000000000000956 · Cited by 257
“of systemic estrogen have been demonstrated in observational studies.(13-17) Therefore, large prospective observational studies might demonstrate whether vaginal estrogen use confers”
BackgroundRethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho, L., Kaunitz, A. M., Faubion, S. S., Hayes, S. N., Lau, E. S., Pristera, N., Scott, N., Shifren, J. L., Shufelt, C. L., Stuenkel, C. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.061559 · Cited by 205
Metadata
- Authors
- Bergendal, A., Kieler, H., Sundström, A., Hirschberg, A. L., & Kocoska-Maras, L.
- Affiliations
- Karolinska Institutet (SE)
- Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- Venue
- Menopause
- Published
- 2016-06
- Volume
- 23
- Issue
- 6
- Pages
- 593-599
- ISSN
- 1072-3714 (ISSN-L)
- 1530-0374
- OpenAlex
- W2327965756
- Cited by
- 90
- References
- 32
- Citations by year
- 2026: 10 · 2025: 8 · 2024: 6 · 2023: 9 · 2022: 7 · 2021: 5 · 2020: 7 · 2019: 8 · 2018: 12 · 2017: 14 · 2016: 3
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Menopause The Journal of The North American Menopause Society (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- venous thromboembolism, hormone therapy, estrogen-progestin combination, estrogen-only therapy, transdermal estrogen, route of administration, medroxyprogesterone acetate, norethisterone acetate, peri- and postmenopausal women, thrombosis risk
- MeSH terms
- Norethindrone Acetate, Administration, Cutaneous, Administration, Oral, Estrogens, Female, Humans, Menopause, Middle Aged, Norethindrone, Progestins, Risk Factors, Sweden, Vagina, Estrogen Replacement Therapy, Logistic Models, Odds Ratio, Case-Control Studies, Medroxyprogesterone Acetate, Postmenopause, Perimenopause, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. https://app.cochat.ai/papers/10.1097/gme.0000000000000611
- The paper
- Bergendal, A., Kieler, H., Sundström, A., Hirschberg, A. L., & Kocoska-Maras, L. (2016). Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration. Menopause. https://doi.org/10.1097/gme.0000000000000611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.